Nuvilex Inc.'s (OTCQB: NVLX) shares have lost nearly half of their value since Jul. 21, when the price per share was 33 cents.
On Sept. 19, Nuvilex's share value closed at 18 cents, down 1 cent from its close of 19 cents the previous day, on volume of 1.8 million shares. What's behind the Silver Spring, Md.-based biotech company's slide is open for debate, but some industry observers say the damage is being done by its weak financials.
Nuvilex's recently filed annual report for the year ending Apr. 30, 2014 set off investor alarms by reporting no revenue and a humongous net loss of $27.2 million. Some industry observers also raised their eyebrows at the $13.9 million in the stock Nuvilex awarded and split evenly among four of its top executives.
Massive PR Push
Meanwhile, Nuvilex's PR machine is churning out a myriad of positive press releases touting every major and minor test, agreement or trial the company is involved in.
They include publicizing Nuvilex's worldwide rights to use the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology for the development of a treatment for pancreatic cancer. The fact the company is preparing to conduct a Phase 2b clinical trial in patients with advanced, inoperable pancreatic cancer is also being publicized.
While these are definitely positive developments, the challenge for any potential investor in this penny stock is to estimate just how long it will take for these accomplishments to turnaround its massive net loss – or if that's even possible.
Find out what could be the best investor's move when it comes to NVLX by getting the complete report here, or by cutting and pasting the following link in your Web browser:
www.pennypickalerts.com
Cannabis Science Acquires Use of Patented Delivery System
Colorado Springs, Colo.-based Cannabis Science Inc.'s (OTCQB: CBIS) share volume soared Sept. 19, with more than 5.9 million shares changing hands, significantly higher than its 30-day average volume of 3.5 million shares.
The sudden surge comes on the heels of the company's Sept. 17 announcement that it had signed a globally-exclusive, collaborative agreement with multinational company Unistraw Holdings Pte. Ltd.
The agreement allows Cannabis Science to deliver cannabis and hemp extracts and pure cannabinoid-based products using the patented Unistraw Delivery System. It also calls for Cannabis Science and Unistraw to form a joint venture to further refine, develop, and bring to market a variety of proprietary cannabis, hemp, and cannabinoid-based nutraceutical and pharmaceutical products.
While this is one of many positive press releases Cannabis Science has been pumping out recently, industry observers point out that the company has yet to complete a product. Plus, it latest 10Q, covering the period ending Jun. 30, doesn't paint a pretty picture:
- Net loss: $1.5 million
- No revenue
- Current liabilities: $4.2 million
- Current liabilities: $4.2 million
- Cash: $791,400On Sept. 19, CBIS' share price closed at 6 cents, unchanged from its closing price of the previous day.
Find out what could be the best investor's move when it comes to CBIS by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Is Medical Marijuana Inc. another Weed Company Stuck in a Rut?
On Sept. 19, Medical Marijuana Inc.'s (OTCPINK: MJNA) share price closed at 19 cents, unchanged from its closing price of the previous day, on volume of 4 million shares.
The San Diego, medical marijuana company has not made any substantial announcements or made any news lately, yet its share value, along with many other marijuana stocks has been on a downward trend for months. In Medical Marijuana's case, its shares have lost almost half of their value since June.
Some industry observers say this is due in part to the fact that the marijuana mecca that was supposed to be born from the wholesale legalization of cannabis has yet to materialize. On the contrary, in some states the push for the legalization of weed has actually stiffened opposition.
As a result, the initial investor enthusiasm for marijuana stocks has soured mightily.
Find out what could be the best investor's move when it comes to MJNA by getting the complete report here, or by cutting and pasting the following link in your Web browser:
ABOUT US:
www.pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.
www.pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
www.pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: www.pennypickalerts.com
Disclosure
www.pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.